Clinical Trials

A prospective, multinational, multi-center, phase 2, randomized, controlled, open-label study evaluating the efficacy, safety, tolerability and pharmacokinetics of sig12d-loder in the treatment of patients with unresectable locally advanced pancreatic cancer when used in conjunction with standard chemotherapy (gemcitabine+nab-paclitaxel) versus chemotherapy (gemcitabine+nab-paclitaxel) alone


Study ID
Silenseed SLSG12D-P2

NCT Number
NCT01676259 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0732

Principle Investigator
Dr. Martin Gutierrez

Phase
II

Sponsor
Silenseed


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now